CIS-DIAMMINEDICHLOROPLATINUM II
Metastatic Malignant Neoplasm in the Lung
Roswell Park Cancer InstituteSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Metastatic Malignant Neoplasm in the Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Indocyanine Green M.D. Anderson Cancer Center | Phase 2 | CCC |
HAFNIUM OXIDE M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Cediranib Roswell Park Cancer Institute | Phase 1 | CC |
Iopamidol Stanford University | Phase 1 | CC |
Nivolumab Mayo Clinic | Phase 1 | CC |
Sargramostim Mayo Clinic | Phase 1 | CC |
18f-αvβ6-bp Julie L. Sutcliffe, Ph.D | Early Phase 1 | C |
Doxepin Mayo Clinic | Phase 2 | C |
Same molecule, other indications
CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →